C
Coherus Oncology, Inc. (CHRS)
NGM – Real Time Price. Currency in USD
1.50
+0.02 (1.35%)
At close: Jun 26, 2026, 4:00 PM EDT
1.50
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
1.50
+0.02 (1.35%)
At close: Jun 26, 2026, 4:00 PM EDT
1.50
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $115.2M significantly exceed its total debt $54.4M, ensuring strong financial flexibility
Total current assets $206.0M exceed Total current liabilities $132.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.7) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-16.5x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$57.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.56 | 6.05 | 8.0 | |
| Quick ratio | 1.52 | 5.63 | 8.0 | |
| Debt to Equity | 0.69 | 0.30 | 7.0 | |
| Debt to Assets | 0.20 | 1.04 | 8.0 | |
| Interest coverage | -16.54 | -16.91 | 1.0 | |
| Weighted average score | 6.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 211M | 257M | 26M | 42M | 47M |
| Gross Profit | 137M | 94M | 12M | 24M | 28M |
| Operating Income | -257M | -193M | -193M | -180M | -170M |
| Net Income | -292M | -238M | -148M | -170M | -152M |
| EBITDA | -253M | -189M | -188M | -176M | -166M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 40.49 | 37.18 | 10 |
| Next quarter | 44.26 | 25.81 | 10 |
| Current year | 46.11 | 34.94 | 10 |
| Next year | 43.13 | 37.14 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -3.43 | -1.76 | 30.77 | -193.59 | 3.3 |
| Y/Y | 61.99 | 32.93 | 34.15 | -124.13 | 7.8 |
| 3y average | -2.67 | 13.74 | -193.79 | -153.78 | 2.8 |
| 5y average | -14.94 | -55.49 | -183.04 | -223.13 | 1.0 |
| Weighted average score | 3.7 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |